机器人辅助腹腔镜膀胱癌近距离放疗导管植入术
本研究描述了2011年6月至2016年5月26例cN0M0孤立性T1G3或≤5cm的T2G1-3尿路上皮癌或cN0M0脐尿管癌患者接受机器人辅助腹腔镜近距离放疗导管植入术的技术与围手术期结局,导管植入成功率92%,中位随访12个月,1年无病生存率74%、2年63%,作者认为该技术可行,可作为开放手术的微创替代方案。
要点
- 机器人辅助腹腔镜近距离放疗导管植入术在92%的患者中成功完成。
- 1年无病生存率74%,2年63%;1年和2年局部无复发生存率均为80%。
- 早期(≤30天)高级别并发症(Clavien-Dindo≥3)发生率为8%。
核心结论
- 作者认为机器人辅助腹腔镜近距离放疗导管植入术在技术上可行,在选定患者中可作为开放手术的安全微创替代方案。
- 作者指出本研究结果需在更大规模的研究中加以确认。
研究设计与样本
- 研究纳入2011年6月至2016年5月间26例cN0M0孤立性T1G3或≤5cm的T2G1-3尿路上皮癌或cN0M0脐尿管癌患者。
- 患者计划接受外照射放疗(20次×2Gy)、机器人辅助腹腔镜近距离放疗导管植入术以及脉冲剂量率(29次×1.04Gy)或高剂量率(10次×2.50Gy)近距离放疗。
- 中位随访时间为12个月(四分位距4-20)。
主要发现
- 近距离放疗导管植入成功率为92%。
- 中位住院时间为5天(四分位距4-7天),所有病例失血量均<50ml。
- 1年无病生存率为74%,2年无病生存率为63%。
- 1年和2年局部无复发生存率均为80%,1年和2年免膀胱切除生存率均为87%。
- 早期(≤30天)高级别并发症(Clavien-Dindo≥3)发生率为8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究受样本量小限制。
- 研究受随访时间短限制。
- 作者指出本研究结果需在更大规模的研究中加以确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Robot-assisted laparoscopic (RAL) implantation of brachytherapy catheters (BTCs) can be a minimally invasive alternative to open retropubic implantation. Descriptions of the surgical technique and outcomes are sparse. OBJECTIVE: To describe our technique and perioperative outcomes for RAL BTC implantation in urothelial carcinoma (UC) and urachal carcinoma (UraC). DESIGN, SETTING AND PARTICIPANTS: Between June 2011 and May 2016, 26 patients with cN0M0 solitary T1G3 or T2G1-3 UC of ≤5cm or cN0M0 UraC were scheduled for external beam radiotherapy (20×2Gy), RAL BTC implantation, and pulsed-dose (29×1.04Gy) or high-dose rate brachytherapy (10×2.50Gy). Median follow-up was 12 mo (interquartile range 4-20). SURGICAL PROCEDURE: RAL BTC implantation with or without pelvic lymph node dissection and/or partial cystectomy. MEASUREMENTS AND STATISTICAL ANALYSIS: Perioperative data, complications, disease-free-survival (DFS), local recurrence-free survival (LRFS), and cystectomy-free survival (CFS) were evaluated as well as the feasibility of the technique. RESULTS AND LIMITATIONS: BTC implantation was successful in 92% of the patients. Median hospitalisation was 5 d (interquartile range 4-7) and blood loss <50ml in all cases. DFS was 74% at 1 yr and 63% at 2 yr. LRFS was 80% at 1 and 2 yr, and CFS was 87% at 1 and 2 yr. Early (≤30 d) high-grade complications (Clavien-Dindo ≥3) occurred in 8% of the patients. The study is limited by the small sample size and short follow-up time. CONCLUSIONS: RAL BTC implantation is technically feasible and could serve as safe, minimally invasive alternative to open surgery in selected patients. The results of this study should be confirmed in larger studies. PATIENT SUMMARY: Brachytherapy catheter (BTC) implantation is traditionally carried out via open retropubic surgery. We describe robot-assisted laparoscopic BTC implantation as a minimally invasive alternative. Perioperative outcomes are described and confirm the safety and feasibility of this procedure.
引用
- Bosschieter J, Vis AN, van der Poel HG, et al. Robot-assisted Laparoscopic Implantation of Brachytherapy Catheters in Bladder Cancer. Eur Urol. 2017. PMID: 28619396. doi:10.1016/j.eururo.2017.05.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。